Arbutus Biopharma Corp

Arbutus Biopharma plans to launch a modified Dutch auction tender offer to repurchase up to $230 million of its common shares at $5 to $5.75 per share. The offer is expected to begin on or around August 24 and expire around September 29, with the company using cash on hand to fund the repurchases. Stock rose 12% in Friday premarket trading.

Moderna's stock surged 176.9% to $174.38 on August 19, 2026, lifting its market capitalization to roughly $69.6 billion and strengthening its acquisition currency. The company still guides to a year-end 2026 cash and investments balance of between $4.7 billion and $5.2 billion, plus an undrawn $0.9 billion credit facility, and the $950 million Arbutus/Genevant settlement is largely resolved. CEO Stéphane Bancel said Moderna is preparing for "the growth stage of a company coming ahead of us," though management has not signaled M&A intent. Potential targets include Immatics, with a $1.3 billion market cap and an existing collaboration; Arbutus Biopharma, at $957.6 million, whose acquisition would extinguish $1.3 billion in contingent LNP patent exposure; Intellia Therapeutics, at $1.9 billion, with Phase 3 lonvo-z showing an 87% reduction in hereditary angioedema attacks; and Editas Medicine, at $442.3 million, offering cardiometabolic pipeline access.

Immunovant reported a cash balance of $797.8 million as of June 30, 2026, which management stated provides a runway to the potential commercial launch of IMVT-1402 in Graves' disease. Research and development expenses were $142.6 million for the quarter, compared to $101.2 million in the prior year, primarily due to increased clinical trial activities for IMVT-1402 and contract manufacturing costs. The company reported a net loss of $153.2 million, or $0.75 per common share, for the three months ended June 30, 2026, and a non-GAAP net loss of $139.4 million excluding $13.8 million in non-cash stock-based compensation. Management expects topline data from the proof-of-concept trial in cutaneous lupus erythematosus in the second half of 2026, and topline data for the potentially registrational trials in Graves' disease and myasthenia gravis in calendar year 2027. Roivant, the parent company, received an upfront payment of $950 million from the Moderna settlement, with $770 million allocated to Genevant and the remainder to Arbutus, and reported a cash balance of just under $4 billion prior to the receipt of the Moderna settlement funds.

Arbutus Biopharma reported second quarter 2026 financial results and announced it received a first payment of approximately $178 million in July from its $950 million settlement with Moderna, and expects to return up to approximately $230 million to shareholders through share repurchases starting in the third quarter. The company also filed three international patent infringement lawsuits against Pfizer and BioNTech related to its lipid nanoparticle technology, and achieved alignment with the FDA on a Phase 2b clinical trial design for its chronic hepatitis B drug candidate imdusiran. As of June 30, 2026, Arbutus held cash, cash equivalents and marketable securities of $92.6 million, and reported a net loss of $5.1 million for the quarter.

Pfizer is facing expanded patent litigation from Arbutus Biopharma and Genevant Sciences over mRNA lipid nanoparticle technology, with new international cases adding legal and operational questions for its COVID-19 vaccine business. The most followed valuation narrative pegs Pfizer's fair value at about $29.19 per share versus a recent close of $24.94, suggesting the stock is materially discounted once future cash flows are adjusted using a 7.11% discount rate. This narrative assumes robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, will drive sustained long-term revenue and earnings growth. However, the outlook depends on Pfizer offsetting revenue headwinds and patent expiries, and on regulators not imposing tighter pricing rules that squeeze long-term margins. The stock showed a 1-day return of 0.77% and a 7-day return of 2.85%, but a 90-day decline of 6.94%, while the 1-year total shareholder return stands at 6.14%.

Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines, extending the legal dispute beyond the existing U.S. litigation into Canada and several European countries under the Unified Patent Court. The lawsuits seek monetary damages and permanent injunctions that could, in a worst-case scenario, affect Pfizer's ability to sell the vaccines in some markets. The dispute centers on lipid nanoparticle technology used in mRNA delivery, adding legal and operational risks to Pfizer's key vaccine franchise. Pfizer's stock last closed at $25.05, with a 10.5% gain over the past year but declines of 19.5% over three years and 22.6% over five years. The legal process is typically lengthy, giving Pfizer time to pursue defenses or settlements, but investors now face another potential source of cash outflows and operational constraints.